Historically, CBG was an unknown cannabinoid in Hemp and Marijuana (Cannabis Sativa L). Its small quantities made it difficult for further experimentation in medicinal use. Although some breeding work had yielded cannabis chemotypes lacking in downstream enzymes that express 100% of their Phyto cannabinoid content as CBG (de Meijer and Hammond, 2005; de Meijer et al., 2009a).
A 1990 study examined CBG for lowering intraocular pressure, making it a possible glaucoma treatment. In a 2008 study, it was found to be a possible benefit in the treatment of MRSA due to its antibacterial and antifungal properties. A December 2014 study explored CBG as a possible agent to combat colorectal cancer.
The neuroprotective properties of CBG were the subject of a January 2015 study, suggesting a therapeutic potential for Huntington’s disease. CBG also showed to be a particularly effective cannabinoid in a June 2015 study that focused on bladder dysfunction treatment. An October 2016 study showed CBG to be potentially effective for sleep, mood and appetite.